614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III

Longitudinal clonotype tracking by next generation sequencing NGS based T cell receptor TCR rearrangement measurable residual disease MRD assay in frontline adult T acute lymphoblastic leukemia ALL

Prognostic significance of IKZF1 deletion subtypes in ph negative BCP ALL Biallelic null deletion predicts the worst survival in TP53 wild type patients

Unveiling FLT3 in B ALL Molecular drivers and targeted treatment opportunities

Unannotated open reading frames expand the antigen repertoire in T cell acute lymphoblastic leukemia

Comparison of paired bone marrow and peripheral blood measurable residual disease in pediatric acute lymphoblastic leukemia by next generation sequencing A report from the dana farber ALL consortium protocol 16 001

A proteomic signature derived by ensemble machine learning for predicting relapse in pediatric B cell acute lymphoblastic leukemia

Crosstalk between CEP72 germline polymorphism and NOTCH1 somatic mutations alters the sensitivity of leukemia cells and normal T cells to vincristine influencing the prognosis of pediatric T ALL

Development of an individualized prognostic model based on gut microbiota–related genes in pediatric ALL A study from the target cohort

ALL pharmacotyping data portal An open source platform for exploring genomics of leukemia drug susceptibility and resistance

Tumor induced dendritic cell dysfunction impairs T cell proliferation and confers poor prognosis in high risk acute lymphoblastic leukemia

Ph like B cell acute lymphoblastic leukemia in a Mexican pediatric cohort Molecular features and prognostic implications